Introduction
The vav1 proto-oncogene was first identified as a result of its dysregulated activation following DNA insertional mutagenesis (Katzav et al., 1989) . Vav1, as well as two related proteins, Vav2 and Vav3, contain Dbl and pleckstrin homology domains and function as guanosine nucleotide exchange factors (GEFs) that activate specific members of the Rho GTPase family (Crespo et al., 1997; Bustelo, 2000) . Unlike most GEFs, catalytic activity of Vav proteins is tightly regulated by direct phosphorylation of tyrosine residues in the amino terminus (Lopez-Lago et al., 2000) . In addition, Vav1 also serves as an important signaling molecule in GEF-independent pathways (Kuhne et al., 2000) . Activation of receptor tyrosine kinases, antigen receptors and G protein-coupled receptors induces phosphorylation on tyrosine residues in Vav proteins (Bustelo, 2000) . Thus, Vav proteins can serve as unique molecular linkers between diverse signaling receptors and Rho GTPase signaling pathways.
Vav1 is predominantly expressed in hematopoietic and trophoblast cells (Katzav et al., 1989; Zmuidzinas et al., 1995) , while Vav2 and Vav3 are more broadly expressed (Schuebel et al., 1996; Movilla and Bustelo, 1999) . Three Vav proteins share 50-60% amino-acid homology and have been demonstrated to exert both redundant and specific functions in hematopoietic cells as defined by studies of mice lacking these genes (Bustelo, 2000; Fujikawa et al., 2003) . Vav1 is the best characterized family member. Vav1-deficient T cells demonstrate defective T-cell receptor-induced proliferation, calcium flux, IL-2 production and actin cytoskeleton rearrangement (Bustelo, 2000) . Vav1
À/À mast cells display impaired FceR-mediated degranulation and cytokine production (Manetz et al., 2001) . Also, it has recently been shown that Vav1 and Vav3 are essential for b2 integrin-dependent neutrophil adhesion and phagocytosis via b2 integrin signaling through Rho GTPases (Gakidis et al., 2004) .
The GEF catalytic activity of Vav1 appears relatively specific to members of the Rac subfamily of Rho GTPases (Rac1 and Rac2) and Vav1 appears to regulate RhoA and Cdc42 activation to a lesser extent (Crespo et al., 1997; Schuebel et al., 1998) , although direct substrates of Vav1 in primary hematopoietic lineages remain to be delineated. The Rac subfamily contains three members, Rac1, Rac2 and Rac3. Rac2 is expressed in an hematopoietic-specific fashion, while Rac1 and Rac3 are ubiquitously expressed (Shirsat et al., 1990; Moll et al., 1991; Diekmann et al., 1995) . Using genetargeted mice lacking Rac1 and/or Rac2, we and others have shown that these two Rac proteins play essential roles in multiple hematopoietic lineages. In particular, Rac2 acts as a key regulator of phosphoinositide 3-kinase (PI-3K)/Akt-mediated antiapoptotic pathway, whereas Rac1 is required for G1/S cycle progression through regulation of cyclin D1 expression and mitogenactivated protein kinase activation in hematopoietic stem/progenitor cells (HSC/Ps) (Gu et al., 2003) . Rac2 is also required for activation of PI-3K/Akt pathway and mediates stem cell factor (SCF)-induced cell survival via regulating BAD/Bcl-xL expression in primary mast cells . SCF stimulates tyrosine phosphorylation of Vav1 in hematopoietic cells (Alai et al., 1992) . Thus, one possible function of Vav1 is to integrate ligand-induced c-Kit receptor activation and Racmediated signaling in regulation of proliferation and survival of hematopoietic cells.
Vav1 has been implicated in the transformation of fibroblasts. Oncogenic mutations of Vav1 include a deletion of the amino-terminal helix-loop-helix domain (Katzav et al., 1991) or a substitution of tyrosine to phenylalanine at residue 174 (Lopez-Lago et al., 2000) . Ectopically expressed Vav1 has also been demonstrated to induce growth factor-stimulated proliferation in pancreatic tumor cells and has been implicated in neuroblastoma and pancreatic cancer tumorigenesis (Betz et al., 2003; Hornstein et al., 2003; Fernandez-Zapico et al., 2005) . While these findings elucidate important biochemical and transforming properties of Vav1, the biologic effect(s) of expression of oncogenic Vav1 mutants in primary hematopoietic cells have yet to be addressed.
Here, we have demonstrated that overexpression of an oncogenic Vav1 mutant, but not wild-type (WT) Vav1 induces apoptosis rather than uncontrolled growth in vitro in the presence of SCF stimulation in primary hematopoietic progenitor cells (HPCs) and inhibits engraftment of HSC/Ps in vivo. The oncogenic Vav1-induced apoptosis is associated with reduced expression of the antiapoptotic proteins Bcl-2 and Bcl-xL. We also show that expression of oncogenic Vav1 is associated with sustained activation of Rac1 and Rac2, not Cdc42, in the transduced HPCs. Oncogenic Vav1-induced apoptosis is Rac-dependent in HPC and a constitutively activated Rac mutant is sufficient to induce apoptosis at a similar level. Furthermore, we show that loss of p53 increases Bcl-2 and Bcl-xL and greatly suppresses oncogenic Vav1-induced apoptosis in HPCs. In marked contrast to its expression in WT cells and WT Vav1 expression in p53 À/À cells, oncogenic Vav1 collaborates with p53 deficiency to enhance self-renewal capability and proliferation of HPCs.
Results
Expression of oncogenic Vav1 in primary hematopoietic cells induces apoptosis in vitro and inhibits engraftment in vivo To express WT Vav1 and its oncogenic mutant (Vav1D180) in primary hematopoietic cells, we cloned the HA-tagged Vav1 cDNAs into a bi-cistronic retroviral vector expressing EGFP (Figure 1a ; Williams et al., 2000) . Unlike other GEFs, catalytic activity of Vav1 is regulated by phosphorylation of the tyrosine(Y) located in the acidic region at residue 174 (Aghazadeh et al., 2000) . The truncated Vav1D180 protein does not contain the amino terminus calponin homology domain and acidic region and lacks the Y174 residue. Consequently, this mutant has been shown to be constitutively active with respect to GEF activity. Vav1D180 has been shown to have strong transforming activity as analysed using the NIH/3T3 transformation assay (Bustelo, 2000) . Freshly isolated low-density bone marrow (LDBM) cells were infected with each retroviral construct and sorted for c-Kit þ , EGFP þ cells (c-Kit used as a marker for the primitive HPCs). This was associated with a lower retroviral transduction rate (%EGFP þ : 15% Vav1D180 vs 72% WT Vav1) and lower mean fluorescence intensity of Vav1D180-transduced cells compared with WT Vav1-transduced cells. Expression of Vav1D180 in these cells was consistently lower than that of WT Vav1 as measured by immunoblot analysis (Figure 1b ). These data suggest that the ectopic expression of high levels of Vav1D180, but not WT Vav1, may be deleterious.
To determine the effects of WT Vav1 and Vav1D180 expression on cytokine-stimulated cell growth, we cultured transduced HPCs in the presence of SCF, a survival and growth factor for primitive hematopoietic cells and the ligand for the receptor tyrosine kinase, c-Kit (Alai et al., 1992) . In contrast to previous findings in fibroblasts (Bustelo, 2000) , expression of Vav1D180 led to significantly reduced expansion of HPCs after SCF stimulation and a reduction in the growth of HPC in a colony assay in response to multiple cytokines, compared with either an empty vector (as control) or WT Vav1 (Figure 1c and d) . In addition, expression of Vav1D180, but not WT Vav1 and control vector, increased apoptosis as measured by the frequency of early apoptotic (Annexin V þ ) cells and late apoptotic/ necrotic (Annexin V þ and 7-AAD þ ) cells more than four-folds (Figure 1e ). However, by thymidine incorporation both WT Vav1-and Vav1D180-transduced HPCs displayed a two-fold increase in proliferation in response to SCF compared with control cells (Figure 1f ). Together, these data suggest that expression of Vav1D180 is associated with significantly increased apoptosis that biologically overshadows a concomitant increase in proliferation. In contrast, overexpression of WT Vav1 in HPCs had no affect on cell apoptosis. HSC/P is multipotent and capable to reconstitute hematopoiesis in lethally irradiated recipient mice. We next examined whether Vav1D180 affects engraftment and reconstitution of HSC/Ps using a competitive engraftment assay (Gu et al., 2005 (Figure 1g) . Similarly, at 4 months post-transplantation, the BM chimerism of Vav1D180 recipient mice was significantly lower than that of control and WT Vav1 recipient mice (%EGFP þ 7s.d.: 4.671.8 Vav1D180 vs 2476 control and 2877 WT Vav1. n>15 mice per group. Po0.01). Despite the reduced engraftment, Vav1D180-transduced donor cells gave rise to a normal distribution of hematopoietic lineages including myeloid (Gr-1 þ ), T (CD3 þ ) and B (B220 þ ) cells as analysed by flow cytometry of PB, BM, spleen and thymus (data not shown). None of these recipient mice showed increased leukocyte counts or leukemic phenotypes up to 6 months post-transplantation, when they were sacrificed for analysis.
Vav1D180 induces sustained activation of Rac1 and Rac2 and active Rac mutant is sufficient to induce HPC apoptosis To determine whether Vav1D180 activates Rac and/or Cdc42 in the transduced HPCs, we measured levels of the active, GTP-bound Rac1, Rac2 and Cdc42 using an effector pull-down assay in the absence or presence of SCF (Benard et al., 1999) . As shown in Figure 2a , GTPbound Rac was detected in control cells only after SCF stimulation. In contrast, expression of Vav1D180 was associated with elevated levels of Rac1-GTP and Rac2-GTP in the absence of stimulation. SCF stimulation further increased activation of Rac1 and Rac2. Overexpression of WT Vav1 increased levels of the GTPbound Rac proteins only after SCF stimulation with no Rac-GTP demonstrated in the absence of stimulation. Levels of Cdc42-GTP were low and not affected by the expression of either WT Vav1 or Vav1D180, but increased after SCF stimulation (Figure 2a) . Therefore, these data suggest that expression of Vav1D180 but not WT Vav1 dysregulates the activation of Rac GTPases, leading to sustained activation of Rac1 and Rac2 in HPCs in the absence of stimulation.
We have previously demonstrated that Rac1 and Rac2 are critical regulators of signaling pathways controlling cell proliferation and survival in primary hematopoietic cells (Gu et al., 2003; Walmsley et al., 2003) . We next asked whether sustained activation of Rac proteins associated with Vav1D180 expression could account for the increased apoptosis in these cells. To test this, we introduced an active Rac mutant into HPCs. It has been demonstrated that active mutants of Rho GTPases including Rac proteins loss their specific /ml cells were plated in methylcellulose containing 100 ng/ml of G-CSF, MGDF and SCF. Colonies were enumerated using an inverted microscope at day 7. (e) Cell apoptosis. Cells were stained with Annexin V-APC and 7-AAD after 100 ng/ml SCF stimulation for 48 h and analysed by flow cytometry. (f) Cell proliferation. Cells were starved in 1% serum-containing medium for 8 h and stimulated with 100 ng/ml SCF for 48 h. Vav1 signaling in hematopoietic progenitor growth Y Gu et al subcellular localization (Michaelson et al., 2001) , which is associated with specific function of Rac1 and Rac2 in hematopoietic cells (Filippi et al., 2004) . Therefore, we here used Rac1L28 to increase total Rac activities in HPCs. The Rac1L28 mutant possesses an increased intrinsic rate of exchange of GDP by GTP and leads to constitutively increased levels of the GTP-bound Rac independent of mitogenic stimulation (Lin et al., 1999) . Similar to Vav1D180, Rac1L28 expression led to a twofold reduction in clonogenic growth ( Figure 2b ) and a three-fold increase in the frequency of early apoptotic cells and late apoptotic/necrotic cells compared with control cells (Figure 2c ). Thus, sustained activation of Rac induced by either Vav1D180 or Rac1L28 expression is sufficient to induce abnormal apoptosis in HPCs.
Apoptosis induced by Vav1D180 is Rac-dependent
To further examine whether the Vav1D180-induced apoptosis is Rac-dependent, we expressed Vav1D180 in HPCs genetically deficient for both Rac1 and Rac2 genes. In agreement with previous reports (Gu et al., 2003) , Rac1 HPCs. In addition, we made a GEF-deficient mutant (N364A/E365A) in the DH domain of oncogenic Vav1 (Debreceni et al., 2004) to confirm that Vav1D180-induced apoptosis of HPCs is dependent on its GEF activity. In contrast to Vav1D180, expression of N364A/ E365A Vav1D180 in WT HPCs did not induce apoptosis or proliferation compared with control cells (Figure 3d-f) . These results, along with the observation of increased apoptosis associated with expression of the active Rac1L28 mutant, suggest that Rac activation is required for the Vav1D180-induced HPC apoptosis and proliferation phenotypes.
Vav1D180 or Rac1L28 suppress Bcl-2 and Bcl-xL protein expression Rac2 is required for HPC survival in part through regulation of the PI-3K/Akt-mediated antiapoptotic pathway, while Rac1 is required for cell cycle progression via regulation of extracellular signal-regulated kinase (ERK) activation (Gu et al., 2003) . As shown in Figure 4a , expression of either Vav1D180 or Rac1L28 in HPCs did not significantly affect phosphorylation of Akt in response to SCF stimulation. However, both Vav1D180 and Rac1L28 moderately enhanced phosphorylation of ERK1 after SCF stimulation, correlating with increased proliferation of these cells (Figure 1f ). The Bcl-2 family members, including antiapoptotic proteins (Bcl-2 and Bcl-xL) and proapoptotic proteins (Bax and BAD), play critical roles in regulation of a cytochrome c-dependent apoptotic pathway (Zha et al., 1996; Datta et al., 1997) . Previous studies have demonstrated regulation of Bcl-xL and BAD expression by Rho GTPases in hematopoietic cells, including Rac (Dibbert et al., 1998; Yang et al., 2000) . We next examined expression of the related Bcl-2 family proteins in HPCs expressing Vav1D180 or Rac1L28. As shown in Figure 4b , expression of either Vav1D180 or Rac1L28 was associated with reduced expression of Bcl-2 and BclxL proteins compared with control cells. There was no effect on Bax expression and the level of BAD protein was undetectable in these cells (data not shown).
These data implicate reduced expression of Bcl-2 and Bcl-xL in the increased apoptosis associated with Vav1D180 expression in primary HPCs. To determine whether reduced expression of Bcl-2 family proteins accounts for this apoptotic phenotype associated with Vav1D180 expression, we transduced LDBM cells from Bcl-2 transgenic mice, which overexpress Bcl-2 transgene under a b-actin promoter (Bronson et al., 1996) . In the setting of Bcl-2 transgenic overexpression, Vav1D180 expression did not increase the frequency of early apoptotic cells and late apoptotic/necrotic cells (Figure 4c ). In addition, expression of Vav1D180 promoted proliferation (Figure 4d ) and clonogenic Loss of p53 increases expression of Bcl-2 and Bcl-xL and suppresses Vav1D180-induced apoptosis in HPCs The p53 tumor suppressor has been known as an important regulator of many apoptotic pathways in normal and tumor cells (Wang, 1999) . In fibroblasts, apoptosis induced by depletion of Rac activity via expression of a dominant-negative Rac1N17 mutant requires p53 activity (Lassus et al., 2000) . To examine whether apoptosis induced by oncogenic Vav1 is p53-dependent or not, we expressed Vav1D180 in HPCs from p53 À/À mice. When compared with WT cells, p53
HPCs showed significantly enhanced clonogenic growth ( Figure 5a ) associated with a three-fold reduction in the frequency of early apoptotic cells and late apoptotic/ necrotic cells (Figure 5b ). This reduced apoptosis was associated with increased expression of Bcl-2 and Bcl-xL proteins in p53 À/À cells compared with WT cells (Figure 5c ). Expression of Vav1D180 in p53 À/À cells slightly increased apoptosis (Figure 5b ) compared with control p53
À/À cells, in contrast to the significantly increased apoptosis associated with WT cells expressing Vav1D180 (Figures 1e and 5b) . These results demonstrate that loss of p53 can significantly suppress the apoptotic response of HPCs to Vav1D180 expression, suggesting that the apoptosis is likely induced by both p53-dependent and p53-independent pathways in Vav1D180-transduced HPCs. We next asked whether Vav1D180 modulates expression and/or activation (phosphorylation) of the endogenous p53 in the transduced WT HPCs. We found that Vav1D180 had no affect on expression or phosphorylation levels of p53 in HPCs (data not shown). Also, expression of Vav1D180 did not change the level of Bax, a known downstream effector of p53, in these cells (Figure 4b ). Vav1 signaling in hematopoietic progenitor growth Y Gu et al clonogenic growth (Figure 1d ) in spite of increased proliferation. Therefore, disruption of apoptosis by loss of p53 in Vav1D180-transduced cells would be associated with abnormal cell growth as measured by a serial replating assay, which is used to study self-renewal, proliferation and transforming potential of myeloid progenitors in vitro (Figure 6a ; Lavau et al., 1997) . The transduced WT cells generated colonies after two replatings and resulting secondary colonies were small in size (o30 cells/per colony) and reduced in number (Figure 6b ). Control or WT Vav1-transduced p53 À/À cells were capable of three rounds of replating and secondary colonies were both larger in size (>100 cells/ per colony) and increased in number compared with WT cells (Figure 6b) . Furthermore, Vav1D180-transduced p53 À/À cells gave more serial colonies than control or WT Vav1-transduced p53 À/À cells (Figure 6b ). In addition, control or WT Vav1-transduced p53 À/À cells generated small (o30 cells/per colony) and diffuse tertiary colonies, suggesting their limited self-renewal and proliferation potential. In contrast, VavD180-transduced p53 À/À cells generated larger tertiary colonies (>150 cells/per colony) that were compact or had a compact center and a diffuse halo of differentiating cells (Figure 6c ), similar to colonies derived from primitive hematopoietic progenitors. Importantly, Vav1D180-transduced p53 À/À cells obtained from their tertiary colonies retained proliferation potential in a fourth round of replating (Figure 6b ). Cytospin and WrightGiemsa staining showed that the quaternary colonies of Vav1D180-transduced p53 À/À cells contained both highly proliferative, immature myeloid cells (arrows) and fully differentiated granulocytes and macrophages (asterisk) (Figure 6d ). Flow analysis showed that cells derived from these quaternary colonies were c-Kit
. Also, Vav1D180-transduced p53 À/À cells obtained from their quaternary colonies were able to be cultured in the presence of interleukin (IL)-3 and SCF for 6 weeks. Expression of HA-Vav1D180 protein was confirmed by immunoblot analysis of cultured cells (data not shown). Together, these results demonstrate that in collaboration with p53 deficiency, Vav1D180 enhances self-renewal capacity and proliferation potential of HPCs in vitro.
Discussion
Vav1 is a critical signaling molecule, which is predominantly expressed in hematopoietic cells and contains 
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Rho GEF activity. It preferentially activates the Rac subfamily members, which are essential regulators of proliferation, survival and actin cytoskeleton rearrangement of hematopoietic cells (Bustelo, 2000; Gu et al., 2003) . Using retrovirus-mediated gene transfer in primary HPCs, we have demonstrated that constitutively active Vav1D180 mutant, which results in ligandindependent and sustained activation of Rho GTPases, Rac1 and Rac2, inhibits HPC growth in vitro and engraftment of HSC/Ps in vivo. Expression of Vav1D180 induces apoptosis of the transduced HPCs, attributable to reduced expression of Bcl-2 and Bcl-xL antiapoptotic proteins. In contrast, overexpression of WT Vav1, which increases Rac activities in a ligand-dependent manner, does not have such negative effects on HPC growth and engraftment. Although expression of Vav1D180 is highly transforming in fibroblasts (Bustelo, 2000) , expression of this oncogenic mutant in WT BM cells does not promote self-renewal or proliferation potential of myeloid progenitors as analysed by a serial replating assay. However, Vav1D180 enhances self-renewal and proliferation potential of myeloid progenitors in a p53-deficient background during serial replating passages in vitro, because loss of p53 greatly suppresses the Vav1D180-induced apoptosis in these cells. These results provide evidence for the oncogenic potential of a constitutively active Vav1 mutant in primary cells, which may require collaboration with additional genetic hits such as loss of p53 tumor suppressor. Previous biochemical studies and transient transfection experiments in cell lines have shown that Vav1 has its GEF activity primarily toward to Rac GTPases (Crespo et al., 1997; Schuebel et al., 1998) . However, whether Vav1 activates Cdc42 is less clear (Han et al., 1997; Bustelo, 2000) . Our studies in primary HPCs where Vav1 is normally expressed and functions suggest that Rac1 and Rac2, but not Cdc42, are activated by Vav1, possibly as direct in vivo substrates.
Rac proteins have been known as positive regulators of survival pathways in hematopoietic cells. Using genetargeting approaches, we have shown that Rac1 and Rac2 are required for SCF-induced survival of HPCs through activating PI-3K/Akt antiapoptotic pathway (Gu et al., 2003) . In BM-derived mast cells, loss of Rac2 leads to increased apoptosis associated with impaired activation of Akt and reduced expression of Bcl-xL protein after SCF stimulation . However, it has been shown that expression of WT Vav1 or oncogenic Vav1 in fibroblasts induces Bcl-2-dependent apoptosis through its GEF activity for Rac (Esteve et al., 1998) . We here also demonstrate that constitutive activation of Rac signaling in primary HPCs via expression of Vav1D180 and Rac1L28 mutants induces apoptosis, similar in effect to Rac deficiency. Although we cannot completely exclude the possibility that oncogenic Vav functions through additional pathways to Rac, our results have shown that oncogenic Vav1-induced apoptosis in these cells is dependent on its functional DH domain. Taken together, these findings implicate that properly regulated cycling of Rac is critical for its role in regulating survival/apoptotic pathways in hematopoietic cells. Interestingly, it has also been reported that the active Rac1V12 mutant, when expressed in the hematopoietic BaF3 cell line, blocks cell apoptosis induced by IL-3 deprivation via enhancing PI-3K/Akt activity (Nishida et al., 1999) . This is possibly due to the difference between primary cells and immortalized cell line. The cell lines likely harbor mutations in tumor suppressor pathways, such as p53, and/or in survival/apoptotic pathways, such as Bcl-2 family proteins. Partly in support of this hypothesis, we have shown that loss of p53, which leads to increased expression of Bcl-2 and Bcl-xL proteins, significantly blocks the Vav1D180-induced apoptosis in primary HPCs.
The vav1 gene was first identified during a screen for oncogenes in human tumor cells (Katzav et al., 1989) . Its transforming activity has subsequently been implicated in fibroblasts, especially the N-terminal truncated mutants like Vav1D180 (Katzav et al., 1991; Bustelo, 2000) . Recent findings of ectopic expression of Vav1 in human neuroblastoma (Betz et al., 2003; Hornstein et al., 2003) and pancreatic adenocarcinomas and its stimulatory function in pancreatic tumor cell proliferation further demonstrate an important role of Vav1 in (Joneson and Bar-Sagi, 1999; Nilsson and Cleveland, 2003) . However, in a p53-deficient background, which has increased expression of Bcl-2 and Bcl-xL and significantly reduces spontaneous apoptosis, Vav1D180 enhances self-renewal capacity and promotes proliferation potential of hematopoietic progenitors. Interestingly, unlike in fibroblasts and pancreatic cells, WT Vav1 is not able to induce apoptosis in HPCs or to promote serial replating growth of p53 À/À hematopoietic progenitors. These findings suggest distinct activity between WT Vav1 and oncogenic Vav1 in regulation of proliferation potential and apoptosis of primary hematopoietic cells. One possible explanation of the cell-type specific effects is the distinct expression and/or regulation of Vav1 in hematopoietic cells, which is likely absent in other cells. Taken together, these observations in primary hematopoietic cells suggest the possibility that gain-of-function mutation of vav1 may serve as a genetic hit in promoting hematopoietic cell transformation via enhancing proliferation and self-renewal in a collaborative fashion with another mutation in tumor suppressor pathways or survival/apoptotic pathways.
Materials and methods

Retroviral vectors and transfection
WT Vav1, the truncated mutation with a deletion of first 540 bp of the coding region (Vav1D180), N364A/E365A Vav1D180 and Rac1L28 cDNAs were cloned in a modified MSCV-based bi-cistronic EGFP-expressing vector, MIEG3 (Williams et al., 2000) at BamH1/BglII and EcoRI sites. Three hemagglutinin (HA) tandem repeats were fused to the 5 0 end of cDNAs for transgene detection. Retrovirus supernatant was generated in phoenix-gp cells as previously described (Wahlers et al., 2001) . À/À compound mice after polyI: polyC treatment as described previously (Gu et al., 2003) . To enrich primitive hematopoietic progenitors, mice were injected intraperitoneally with 150 mg/kg 5-Fluorouracil (5-FU, American Pharmaceutical Partners Inc., Los Angeles, CA, USA) in PBS. At 3 days after 5-FU treatment, BM cells were harvested. LDBM cells were purified from fresh BM by centrifugation on a Histopaque-1083 gradient (Gu et al., 2001) . LDBM cells were prestimulated for 2 days in IMDM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum /ml transduced HPCs were plated in methylcellulose containing 10 ng/ml of IL-3. IL-6 and GM-CSF, and 100 ng/ml SCF. Primary colonies were enumerated on day 7. 10 3 -10 4 cells were plated in a secondary assay under same condition. Secondary colonies were enumerated on day 10. The tertiary and quaternary assays were performed in the way same as the secondary replating. Data represent the mean7s.d., n ¼ 3. Vav1 signaling in hematopoietic progenitor growth Y Gu et al (FCS, HyClone, Logan, UT, USA), 2% penicillin and streptomycin (P/S), and 100 ng/ml of recombinant rat SCF, megakaryocyte growth and development factor (MGDF) and granulocyte colony-stimulating factor (G-CSF) (all from Amgen, Thousand Oaks, CA, USA). Then, retrovirusmediated transduction of LDBM cells was performed by published methods (Hanenberg et al., 1997) . At 2 days after transduction, cells were stained with a phycoerythrin (PE)-conjugated anti-mouse CD117 antibody (c-Kit, PharMingen, San Diego, CA, USA). The EGFP þ , c-Kit þ HPCs were purified by fluorescence activated cell sorting (FACS).
Immunoblot analysis and measurement of the active, GTP-bound Rho GTPases Expression of HA-tagged WT Vav1 and Vav1D180 in the transduced HPCs was determined by immunoblot analysis using antihemagglutinin antibody (1:1000, Roche, Indianapolis, IN, USA). The transduced HPCs were stimulated with 100 ng/ml SCF for different time points and then used for immunoblot analyses using antibodies for phospho Akt (Ser473, 1:200), phospho ERK1/2 (p44/p42 (Thr202/Tyr204), 1:1000), total Akt (1:1000), Bcl-xL (1:1000), Bcl-2 (1:200) and Bax (1:1000) (all from Cell Signaling Technology, Beverly, MA, USA).
Levels of the active, GTP-bound Rho GTPases in HPCs after SCF stimulation were measured by an effector pull-down assay as previously described (Gu et al., 2001) . After affinity precipitation, samples were analysed by immunoblot using antibodies specific for Rac1 (1:1000, Cell Signaling Technology), Rac2 (1:5000, a gift from Dr Gary Bokoch, Scripps Institute, La Jolla, CA, USA), and Cdc42 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Analyses of HPC clonogenic growth, proliferation and apoptosis
To examine cell expansion in response to SCF, 1 Â 10 5 EGFP þ , c-Kit þ -sorted HPCs were cultured in medium supplemented with 10% FCS, 2% P/S, 100 ng/ml SCF (Amgen). Cells were enumerated by a hemacytometer every 2 days for 6 days. The clonogenic growth was measured by a progenitor colony forming unit assay using standard methods (Nakahata and Ogawa, 1982) . Briefly, 10 4 /ml cells were plated in triplicate in methylcellulose in presence of 100 ng/ml SCF alone or 100 ng/ml of SCF, G-CSF and MGDF. Colonies were enumerated on day 7 using an inverted microscope.
Cell proliferation in response to SCF was examined by a [ 3 H]thymidine incorporation assay as previously described (Gu et al., 2001) . To determine cell apoptosis, cells were stained with 7-Amino-Actinomycin D (7-AAD) and Allophycocyanin (APC)-conjugated Annexin V (PharMingen) after stimulation with 100 ng/ml SCF for 48 h, and analysed by flow cytometry.
Bone marrow transplantation and engraftment analysis For BM transplantation, a combination of 2 Â 10 5 EGFP þ -sorted BM cells and 8 Â 10 5 untransduced competitor BM cells were injected into tail veins of 6-8 weeks old, lethally irradiated (1100 Rads split dose using a 137 Cs-labeled irradiator) C57BL/6J recipient mice. A total of 15-20 mice were used for each construct. Engraftment of the transduced BM cells (% EGFP þ chimerism) was determined on PB leukocytes monthly up to 4 months after transplantation by flow analysis (Gu et al., 2001) . Expression of HA-tagged WT Vav1 and Vav1D180 in PB and BM cells of the recipient mice was confirmed by immunoblot analysis.
Serial replating assay
To examine self-renewal and proliferation potential of HPCs, a serial replating assay was performed as previously described (Lavau et al., 1997) . Briefly, 10 4 /ml HPCs were plated in methylcellulose containing 10 ng/ml of recombinant murine IL-3, IL-6, granulocyte-macrophage colony stimulating factor (GM-CSF) (All from Pepro Tech, Inc., Rocky Hill, NJ, USA) and 100 ng/ml SCF (Amgen). Primary colonies were enumerated on day 7. Cells from methylcellulose were harvested by PBS wash, and 10 3 -10 4 /ml cells were replated in a secondary assay under identical conditions. After 10 days, secondary colonies were enumerated and tertiary and quaternary assays were performed in the same way. Cells from quaternary colonies were harvested and pooled for long-term culture in medium supplemented with 10% FCS, 2% P/S, 100 ng/ml SCF (Amgen) and 10 ng/ml IL-3 (Pepro Tech., Inc.). Cell culture was passaged every 4-5 days before crisis. To examine cell morphology, cytospin preparation of cells was stained with Wright-Giemsa and examined using a light microscope. To determine cell differentiation status, cultured cells were stained with antibodies specific for c-Kit for primitive cells, Mac-1 and Gr-1 for myeloid cells, CD3 for T cells and B220 for B cells and analysed by flow cytometry.
